Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance
Cancer Cell · 2023-10 · 41 (10) · 1774-1787.e9
DOI: 10.1016/j.ccell.2023.09.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2023-10. Verfasst von Donjeta Gjuka und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, University of Texas, Austin, TX, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Chromosomal region 9p21 containing tumor suppressors CDKN2A/B and methylthioadenosine phosphorylase (MTAP) is one of the most frequent genetic deletions in cancer. 9p21 loss is correlated with reduced tumor-infiltrating lymphocytes (TILs) and resistance to immune checkpoint inhibitor (ICI) therapy. Previously thought to be caused by CDKN2A/B loss, we now show that it is loss of MTAP that leads to poor outcomes on ICI therapy and reduced TIL density. MTAP loss causes accumulation of methylthioadenosine (MTA) both intracellularly and extracellularly and profoundly impairs T cell function via the inhibition of protein arginine methyltransferase 5 (PRMT5) and by adenosine receptor agonism. Administration of MTA-depleting enzymes reverses this immunosuppressive effect, increasing TILs and drastically impairing tumor growth and importantly, synergizes well with ICI therapy. As several studies have shown ICI resistance in 9p21/MTAP null/low patients, we propose that MTA degrading therapeutics may have substantial therapeutic benefit in these patients by enhancing ICI effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Engineering, University of Texas, Austin, TX, USA.
- Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Lank Genitourinary Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Molecular Biosciences, University of Texas, Austin, TX, USA.
- Department of Chemical Engineering, University of Texas, Austin, TX, USA; Department of Molecular Biosciences, University of Texas, Austin, TX, USA.
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- National Institutes of Health
- National Cancer Institute
- AstraZeneca
- U.S. Department of Defense
- V Foundation for Cancer Research
- University of Texas at Austin
Zitieren
APA
Gjuka, D., Adib, E., Garrison, K., Chen, J., Zhang, Y., Li, W., Boutz, D., Lamb, C., Tanno, Y., Nassar, A., El Zarif, T., Kale, N., Rakaee, M., Mouhieddine, T. H., Alaiwi, S. A., Gusev, A., Rogers, T., Gao, J., Georgiou, G., …, & Stone, E. (2023). Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance. Cancer Cell, 41(10), 1774-1787.e9. https://doi.org/10.1016/j.ccell.2023.09.005
Vancouver
Gjuka D, Adib E, Garrison K, Chen J, Zhang Y, Li W, et al. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance. Cancer Cell. 2023;41(10):1774-1787.e9. doi:10.1016/j.ccell.2023.09.005
BibTeX
@article{Gjuka2023,
author = {Gjuka, Donjeta and Adib, Elio and Garrison, Kendra and Chen, Jianfeng and Zhang, Yuxue and Li, Wenjiao and Boutz, Daniel and Lamb, Candice and Tanno, Yuri and Nassar, Amin and El Zarif, Talal and Kale, Neil and Rakaee, Mehrdad and Mouhieddine, Tarek H and Alaiwi, Sarah Abou and Gusev, Alexander and Rogers, Thomas and Gao, Jianjun and Georgiou, George and Kwiatkowski, David J and Stone, Everett},
title = {Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance},
journal = {Cancer Cell},
year = {2023},
volume = {41},
number = {10},
pages = {1774--1787.e9},
doi = {10.1016/j.ccell.2023.09.005}
}
EUVIMED